keyword
MENU ▼
Read by QxMD icon Read
search

EGFR

keyword
https://www.readbyqxmd.com/read/28454414/analysis-of-egfr-mutation-status-in-tissue-and-plasma-for-predicting-response-to-egfr-tkis-in-advanced-non-small-cell-lung-cancer
#1
Yuyan Wang, Jianchun Duan, Hanxiao Chen, Hua Bai, Tongtong An, Jun Zhao, Zhijie Wang, Minglei Zhuo, Shuhang Wang, Jie Wang
The detection of mutations in the epidermal growth factor receptor (EGFR) gene in tumor tissues has been established as the gold standard for predicting the efficacy of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in advanced non-small-cell lung cancer (NSCLC). The current study aimed to investigate whether the presence of co-existing EGFR mutations in tumor tissue and in cell-free tumor DNA (ctDNA) in the plasma predicts a more favorable outcome of EGFR-TKI treatment in advanced NSCLC. A total of 287 NSCLC patients who had undergone EGFR-TKI treatment were enrolled and stratified into four subgroups: Wild-type EGFR in plasma and tissue specimens (B-/T-); mutated EGFR in plasma and tissue specimens (B+/T+); mutated EGFR in only in plasma samples (B+/T-); or mutated EGFR in only tissue specimens (B-/T+)...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454404/correlation-between-epidermal-growth-factor-receptor-mutations-and-the-expression-of-estrogen-receptor-%C3%AE-in-advanced-non-small-cell-lung-cancer
#2
Fang Deng, Ming Li, Wu-Lin Shan, Li-Ting Qian, Shui-Ping Meng, Xiao-Lei Zhang, Bao-Long Wang
Epidermal growth factor receptor (EGFR) mutations are more common in non-small cell lung cancer (NSCLC) and in female patients of East Asian origin. Therefore, the present study investigated the presence of EGFR mutations in advanced NSCLC, and assessed its correlation with clinicopathologic factors, including the expression of estrogen receptor-β (ER-β) and patient prognosis. The present study performed a retrospective analysis of 83 patients with stage IIIB-IV NSCLC. The expression of ER-β and p53 were examined using immunohistochemical methods...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454365/downregulation-of-egfr-in-a-metastatic-brain-lesion-of-egfr-mutated-non-small-cell-lung-cancer-using-a-tyrosine-kinase-inhibitor-a-case-report
#3
Masatoshi Takagaki, Manabu Kinoshita, Kazumi Nishino, Masakazu Nakano, Hiroko Adachi, Morio Ueno, Masanori Kitamura, Yasunori Fujimoto, Kei Tashiro, Yasuhiko Tomita, Fumio Imamura, Toshiki Yoshimine
Brain metastasis is a common complication in patients with cancer, with lung cancer being the most frequent origin of brain metastases. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have begun to serve a pivotal role in lung cancer treatment and have been reported to demonstrate anticancer activity against brain metastases by penetrating the blood-brain barrier. The present study reports, to the best of our knowledge, the first case of EGFR-mutated non-small cell lung cancer (NSCLC) brain metastasis that was surgically resected while the lesion was responding to the EGFR-TKI erlotinib...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454117/elimination-of-lmp1-expressing-cells-from-a-monolayer-of-gastric-cancer-ags-cells
#4
Yoshitaka Sato, Shingo Ochiai, Takayuki Murata, Teru Kanda, Fumi Goshima, Hiroshi Kimura
Epstein-Barr virus (EBV) latently infects malignant epithelial cells in approximately 10% of all gastric cancers. Latent membrane protein 1 (LMP1), an oncogenic protein, plays an important role in malignant transformation in EBV-associated nasopharyngeal carcinoma and B-cell lymphoma; however, its expression has not been detected in EBV-associated gastric cancer. To address why LMP1 has not been detected in EBV-positive gastric tumors, we focused on the interactions between LMP1-positive and -negative cells and stably expressed LMP1 in the gastric cancer cell line AGS...
April 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28454094/proteolytic-cleavages-in-the-extracellular-domain-of-receptor-tyrosine-kinases-by-membrane-associated-serine-proteases
#5
Li-Mei Chen, Karl X Chai
The epithelial extracellular membrane-associated serine proteases matriptase, hepsin, and prostasin are proteolytic modifying enzymes of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR). Matriptase also cleaves the ECD of the vascular endothelial growth factor receptor 2 (VEGFR2) and the angiopoietin receptor Tie2. In this study we tested the hypothesis that these serine proteases may cleave the ECD of additional receptor tyrosine kinases (RTKs). We co-expressed the proteases in an epithelial cell line with Her2, Her3, Her4, insulin receptor (INSR), insulin-like growth factor I receptor (IGF-1R), the platelet-derived growth factor receptors (PDGFRs) α and β, or nerve growth factor receptor A (TrkA)...
April 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/28453880/predicting-postnatal-renal-function-of-prenatally-detected-posterior-urethral-valves-using-fetal-diffusion-weighted-magnetic-resonance-imaging-with-apparent-diffusion-coefficient-determination
#6
Alice Faure, Nicoleta Panait, Michel Panuel, Pierre Alessandrini, Claude D'Ercole, Kathia Chaumoitre, Thierry Merrot
METHODS: Between 2003 and 2014, 11 MRI were performed on fetuses (between 28-32 weeks) in whom second trimester sonography suggested severe bilateral urinary tract anomalies, suspected of PUV. RESULTS: The ADC of the 11 fetuses ranged from 1.3 to 2.86 mm2 s - 1 (median = 1.79 mm2s - 1, normal range for fetal kidney: 1.1-1.8). Two pregnancies with ADC > 2.6 mm2s - 1 were interrupted; the autopsy confirmed PUV and Potter syndrome. For the remaining nine babies, the follow-up was 5...
April 28, 2017: Prenatal Diagnosis
https://www.readbyqxmd.com/read/28453784/detection-of-wtegfr-amplification-and-egfrviii-mutation-in-csf-derived-extracellular-vesicles-of-glioblastoma-patients
#7
Javier M Figueroa, Johan Skog, Johnny Akers, Hongying Li, Ricardo Komotar, Randy Jensen, Florian Ringel, Isaac Yang, Steven Kalkanis, Reid Thompson, Lori LoGuidice, Emily Berghoff, Andrew Parsa, Linda Liau, William Curry, Daniel Cahill, Chetan Bettegowda, Frederick F Lang, E Antonio Chiocca, John Henson, Ryan Kim, Xandra Breakefield, Clark Chen, Karen Messer, Fred Hochberg, Bob S Carter
Background: RNA within extracellular vesicles (EVs) have potential as diagnostic biomarkers for patients with cancer, and are identified in a variety of biofluids. Glioblastomas (GBMs) release EVs containing RNA into cerebrospinal fluid (CSF). Here we describe a multi-institutional study of RNA extracted from CSF-derived EVs of GBM patients, for the presence of tumor-associated amplifications and mutations in the epidermal growth factor receptor (EGFR). Methods: CSF and matching tumor tissue were obtained from patients undergoing resection of GBMs...
April 27, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/28453411/pooled-analysis-of-the-prognostic-and-predictive-effects-of-tp53-comutation-status-combined-with-kras-or-egfr-mutation-in-early-stage-resected-non-small-cell-lung-cancer-in-four-trials-of-adjuvant-chemotherapy
#8
Frances A Shepherd, Benjamin Lacas, Gwénaël Le Teuff, Pierre Hainaut, Pasi A Jänne, Jean-Pierre Pignon, Thierry Le Chevalier, Lesley Seymour, Jean-Yves Douillard, Stephen Graziano, Elizabeth Brambilla, Robert Pirker, Martin Filipits, Robert Kratzke, Jean-Charles Soria, Ming-Sound Tsao
Purpose Our previous work evaluated individual prognostic and predictive roles of TP53, KRAS, and EGFR in non-small-cell lung cancer (NSCLC). In this analysis, we explore the prognostic and predictive roles of TP53/KRAS and TP53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation. Patients and Methods Mutation analyses (wild-type [WT] and mutant) for TP53, KRAS, and EGFR were determined in blinded fashion in multiple laboratories. Primary and secondary end points of pooled analysis were overall survival and disease-free survival...
April 28, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28449534/safety-profile-of-egfr-targeted-hybrid-vector-system-composed-of-pamam-dendrimer-and-oncolytic-adenovirus
#9
COMMENT
A-Rum Yoon, Dayananda Kasala, Jinwoo Hong, Chae-Ok Yun
No abstract text is available yet for this article.
March 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28449488/clinicopathological-features-of-chinese-lung-cancer-patients-with-epidermal-growth-factor-receptor-mutation
#10
Hui Ning, Ming Liu, Lina Wang, Yang Yang, Nan Song, Xiaoxiong Xu, Jin Ju, Gening Jiang
BACKGROUND: Epidermal growth factor receptor (EGFR) gene was the major causative gene of lung cancer and also the specific treatment target. It is necessary to analyze the genotype and phenotype characters of patients. METHODS: We investigated 1,034 lung cancer patients in this study. The collected clinicopathological parameters included gender, age at diagnosis, smoking status, pathological TNM stage, tumor morphology and location, visceral pleural invasion as well as histological type...
March 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28449447/osimertinib-for-advanced-non-small-cell-lung-cancer-harboring-egfr-mutation-exon-20-t790m-acquired-resistant-mutation-for-first-or-second-generation-egfr-tki
#11
EDITORIAL
Yusuke Okuma, Yukio Hosomi
No abstract text is available yet for this article.
March 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28449324/efficacy-and-safety-of-lixisenatide-in-patients-with-type-2-diabetes-and-renal-impairment
#12
M Hanefeld, J M Arteaga, L A Leiter, G Marchesini, E Nikonova, M Shestakova, W Stager, R Gómez-Huelgas
AIMS: This post hoc assessment evaluated the efficacy and safety of once-daily, prandial glucagon-like peptide-1 receptor agonist lixisenatide in patients with type 2 diabetes (T2D) and normal renal function (eGFR ≥90 mL/min), or mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment. METHODS: Patients from nine lixisenatide trials in the GetGoal clinical trial programme were categorized by baseline creatinine clearance: normal renal function (lixisenatide n = 2094, placebo n = 1150); renal impairment (mild: lixisenatide n = 637, placebo n = 414; moderate: lixisenatide n = 122, placebo n = 68)...
April 27, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28449320/a-randomised-double-blind-trial-of-the-safety-and-efficacy-of-omarigliptin-a-once-weekly-dpp-4-inhibitor-in-subjects-with-type-2-diabetes-and-renal-impairment
#13
Antonio Chacra, Ira Gantz, Geraldine Mendizabal, Lucila Durlach, Edward A O'Neill, Zachary Zimmer, Shailaja Suryawanshi, Samuel S Engel, Eseng Lai
AIMS: To assess the safety and efficacy of omarigliptin in subjects with type 2 diabetes mellitus (T2DM) and chronic renal impairment (RI). METHODS: Patients with T2DM with moderate RI (estimated glomerular filtration rate [eGFR] ≥30 to <60 mL/min/1.73 m(2) ) (N=114), severe RI (eGFR <30 mL/min/1.73 m(2) ) (N=55) or end-stage renal disease on dialysis (N=44), who were either not on an antihyperglycaemic agent therapy for at least 12 weeks at screening, washed-off of oral antihyperglycaemic agent monotherapy or low-dose dual combination therapy, or on insulin monotherapy, with baseline glycated haemoglobin (HbA1c) of 6...
April 27, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28449252/serum-phosphorus-levels-and-fracture-following-renal-transplantation
#14
Jasna Aleksova, Phillip Wong, William R Mulley, Kay Weng Choy, Robert McLachlan, Peter R Ebeling, Peter G Kerr, Frances Milat
PURPOSE: Increased fracture rates are observed in renal transplant recipients (RTRs) compared with the general population. Risk factors include age, diabetes, dialysis vintage, immunosuppression, and mineral and bone disorders(1). Low serum phosphorus levels occur post-transplantation; however its relationship with fracture risk has not been evaluated. The purpose of this study was to evaluate risk factors for fracture in RTRs at a single tertiary referral centre. METHODS: A retrospective cross-sectional analysis of 146 patients (75M, 71F) who had been referred for dual energy x-ray densitometry (DXA) post-renal transplantation was performed...
April 27, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28448556/a-highly-specific-and-sensitive-massive-parallel-sequencer-based-test-for-somatic-mutations-in-non-small-cell-lung-cancer
#15
Yoshiaki Inoue, Jun Shiihara, Hitoshi Miyazawa, Hiromitsu Ohta, Megumi Higo, Yoshiaki Nagai, Kunihiko Kobayashi, Yasuo Saijo, Masanori Tsuchida, Mitsuo Nakayama, Koichi Hagiwara
Molecular targeting therapy for non-small cell lung cancer (NSCLC) has clarified the importance of mutation testing when selecting treatment regimens. As a result, multiple-gene mutation tests are urgently needed. We developed a next-generation sequencer (NGS)-based, multi-gene test named the MINtS for investigating driver mutations in both cytological specimens and snap-frozen tissue samples. The MINtS was used to investigate the EGFR, KRAS, BRAF genes from DNA, and the ERBB2, and the ALK, ROS1, and RET fusion genes from RNA...
2017: PloS One
https://www.readbyqxmd.com/read/28448232/dynamic-contrast-enhanced-mr-imaging-parameters-in-bone-metastases-from-non-small-cell-lung-cancer-comparison-between-lesions-with-and-lesions-without-epidermal-growth-factor-receptor-mutation-in-primary-lung-cancer
#16
Hyun Su Kim, Young Cheol Yoon, Soyi Kwon, Ji Hyun Lee, Soohyun Ahn, Hyeon Seon Ahn
Purpose To compare dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging parameters between metastatic bone lesions with and without the epidermal growth factor receptor (EGFR) mutation in consecutive patients with primary non-small cell lung cancer (NSCLC). Materials and Methods This study was approved by the institutional review board. Forty-seven patients with NSCLC and a confirmed EGFR mutation status (27 patients were positive and 26 were negative for EGFR mutation), who underwent DCE MR imaging for bone metastases between November 2012 and March 2016, were included in this study...
April 27, 2017: Radiology
https://www.readbyqxmd.com/read/28447565/risk-factors-for-brain-metastases-in-patients-with-metastatic-colorectal-cancer
#17
Troels Dreier Christensen, Jesper Andreas Palshof, Finn Ole Larsen, Estrid Høgdall, Tim Svenstrup Poulsen, Per Pfeiffer, Benny Vittrup Jensen, Mette Karen Yilmaz, Ib Jarle Christensen, Dorte Nielsen
BACKGROUND: Brain metastases (BM) from colorectal cancer (CRC) are rare, but the incidence is suspected to rise as treatment of metastatic (m) CRC improves. The aim of this study was to identify possible biological and clinical characteristics at initial presentation of mCRC that could predict later risk of developing BM. Furthermore, we wished to estimate the incidence of BM in long-term surviving patients. MATERIAL AND METHODS: We conducted a retrospective study on a Danish multicenter cohort of patients with mCRC who received cetuximab and irinotecan (CetIri) as third-line treatment...
May 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28447439/lipid-abnormalities-in-type-2-diabetes-mellitus-patients-with-overt-nephropathy
#18
Sabitha Palazhy, Vijay Viswanathan
BACKGROUND: Diabetic nephropathy is a major complication of diabetes and an established risk factor for cardiovascular events. Lipid abnormalities occur in patients with diabetic nephropathy, which further increase their risk for cardiovascular events. We compared the degree of dyslipidemia among type 2 diabetes mellitus (T2DM) subjects with and without nephropathy and analyzed the factors associated with nephropathy among them. METHODS: In this retrospective study, T2DM patients with overt nephropathy were enrolled in the study group (n=89) and without nephropathy were enrolled in the control group (n=92)...
April 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/28447036/recent-translational-research-into-targeted-therapy-for-liposarcoma
#19
REVIEW
Rashi Bharat Patel, Ting Li, Zhichao Liao, Jivani Aakash Jaldeepbhai, H A Pavanika N V Perera, Sujani Kaushalya Muthukuda, Dholiya Hardeep Dhirubhai, Vaibhav Singh, Xiaoling Du, Jilong Yang
Liposarcomas (LPS) are among the most common soft tissue sarcomas, originating from adipocytes. Treatment for LPS typically involves surgical resection and radiation therapy, while the use of conventional cytotoxic chemotherapy for unresectable or metastatic LPS remains controversial. This review summarizes the results of recent translational research and trials of novel therapies targeting various genetic and molecular aberrations in different subtypes of LPS. Genetic aberrations such as the 12q13-15 amplicon, genetic amplification of MDM2, CDK4, TOP2A, PTK7, and CHEK1, point mutations in CTNNB1, CDH1, FBXW7, and EPHA1, as the fusion of FUS-DDIT3/EWSR1-DDIT3 are involved in the pathogenesis LPS and represent potential therapeutic candidates...
2017: Stem Cell Investigation
https://www.readbyqxmd.com/read/28446726/low-concentration-of-bpa-induces-mice-spermatocytes-apoptosis-via-gpr30
#20
Chaoliang Wang, Jianxiang Zhang, Qi Li, Tianbiao Zhang, Zishi Deng, Jing Lian, Donghui Jia, Rui Li, Tao Zheng, Xiaoju Ding, Fan Yang, Chao Ma, Rui Wang, Weixing Zhang, Jian Guo Wen
Bisphenol A (BPA) acts as xenoestrogen and has a great impact on disorders of human reproductive system. However, the mechanism through which BPA can affect human testicular function remains to be indentified. GPR30 is a novel membrane estrogen receptor with high-affinity and low-capacity binding to estrogens. We demonstrated that estrogen receptor α (ERα), estrogen receptor β (ERβ) as well as GPR30 are expressed in mouse spermatocyte-derived GC-2 cells using Real-time PCR. We treated the cells with different doses of BPA and found that even low doses of BPA can inhibit GC-2 cell growth using MTT assay...
April 7, 2017: Oncotarget
keyword
keyword
2132
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"